The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Glucocorticoid Use in Rheumatoid Arthritis Management Focus of Ongoing Debate

Glucocorticoid Use in Rheumatoid Arthritis Management Focus of Ongoing Debate

March 1, 2015 • By Gretchen Henkel

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Glucocorticoid Use in Rheumatoid Arthritis Management Focus of Ongoing Debate

Sixty-six years after the discovery of glucocorticoids by Philip S. Hench, Edward Kendall and Tadeus Reichstein, the debate over the use of these powerful drugs in rheumatoid arthritis (RA) continues in the rheumatology community.

You Might Also Like
  • Glucocorticoid Use for Rheumatoid Arthritis Still Sparks Debate
  • Prednisone Might be the Missing Ingredient in the American College of Rheumatology’s Recommendations for Treating Patients with Rheumatoid Arthritis
  • Why Oral Corticosteroids Should Not be Used in Patients with Rheumatoid Arthritis
Explore This Issue
March 2015
Also By This Author
  • Quadruple-threat Rheumatologist

“Few issues in rheumatology evoke the ire of rheumatologists as much as discussions around who should or should not get glucocorticoids,” says Kenneth G. Saag, MD, MSc, Jane Knight Lowe Professor of Medicine, Division of Clinical Immunology and Rheumatology, and director of the Center for Education and Research on Therapeutics (CERTs), Center for Outcomes Effectiveness and Education (COERE), and Center of Research Translation (CORT) in Gout and Hyperuricemia at the University of Alabama at Birmingham. The current debate revolves around questions of whether glucocorticoids should be used as bridge therapy, in long-term low dosages, in low-dose timed-release formulas—or not at all. “This continues to be a contentious topic,” says Dr. Saag.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Why is the question of steroid use still so divisive? We talked recently with those on both sides of the debate and explored the reasons for ongoing diversity of opinion. Clearly, there is not much dissension about use of high-dose steroids in RA. “Although they’re necessary in many serious disorders, we generally do not advocate for chronic high-dose steroid use,” says Dr. Saag. But a number of factors in the past 20 years have reinvigorated the debate for what might constitute safe and effective use of chronic low-dose steroids.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
Dr. Saag
Dr. Saag

Professor Anthony Russell, MD, Division of Rheumatology, Department of Medicine, University of Alberta, Edmonton, Canada, is not a proponent of giving steroids to patients with RA [see “Why Oral Corticosteroids Should Not Be Used in Patients with Rheumatoid Arthritis,” The Rheumatologist (April 2013)]. The debate in favor of steroids, he says, was revived by studies showing that low-dose prednisolone retarded X-ray changes in the joint.1,2,3

Slowing progression of structural damage “is the classic definition of what a DMARD [disease-modifying antirheumatic drug] is,” notes Dr. Saag.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
Dr. Russell
Dr. Russell

Dr. Russell maintains that these studies are responsible for what he calls the “increased fashion” for use of steroids. However, he believes that the time for including steroids in the RA treatment armamentarium has passed. “Yes, they work, but why bother?” he says. “We’ve got good drugs, and we don’t need steroids any more,” he asserts.

Maarten Boers, MD, PhD, MSc, professor of clinical epidemiology and a rheumatologist at VU University Medical Center and the Reade Clinic, Amsterdam, The Netherlands, is a vocal member of the “pro” glucocorticoid camp and has spent his time “trying to get the message across that we should listen to what the data [are] telling us, and that we should give glucocorticoids back their rightful place in the treatment of rheumatoid arthritis.”

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Conditions, DMARDs & Immunosuppressives, Drug Updates, Rheumatoid Arthritis Tagged With: Arthritis, debate, glucocorticoid, Henkel, rheumatologist, Steroid, therapyIssue: March 2015

You Might Also Like:
  • Glucocorticoid Use for Rheumatoid Arthritis Still Sparks Debate
  • Prednisone Might be the Missing Ingredient in the American College of Rheumatology’s Recommendations for Treating Patients with Rheumatoid Arthritis
  • Why Oral Corticosteroids Should Not be Used in Patients with Rheumatoid Arthritis
  • Is Predisone 3 mg/day an Appropriate Dose for Patients with Rheumatoid Arthritis?

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)